Antiarrhythmic
Pregnancy: Use with caution — crosses placenta; neonatal toxicity possible. Short-term IV for maternal arrhythmia acceptable under specialist supervision.
Lidocaine IV (Cardiac Arrhythmia)
Brand names: Xylocard
Adult dose
Dose: Loading: 1-1.5 mg/kg IV bolus over 2 minutes. Maintenance infusion: 1-4 mg/min. Additional boluses: 0.5-0.75 mg/kg if arrhythmia recurs (max 3 mg/kg total in first hour).
Route: Intravenous
Frequency: Loading bolus then continuous infusion
Max: 3 mg/kg total loading; 4 mg/min infusion
Class Ib antiarrhythmic. Alternative to amiodarone for refractory VT/VF when amiodarone unavailable (ERC 2021). Hepatic flow-dependent clearance — reduce infusion rate in HF/elderly.
Paediatric dose
Dose: 1 mg/kg
Route: IV bolus over 2 minutes
Frequency: Loading, then infusion 25-50 mcg/kg/min
Max: 3 mg/kg total loading
Cardiac arrest (paediatric): 1 mg/kg IV/IO if amiodarone unavailable.
Dose adjustments
Renal
No adjustment for short-term use; prolonged infusion in severe renal impairment — monitor for toxic metabolite accumulation
Hepatic
Reduce infusion dose 50% in severe hepatic impairment — extensively hepatically metabolised
Paediatric weight-based calculator
Cardiac arrest (paediatric): 1 mg/kg IV/IO if amiodarone unavailable.
Clinical pearls
- ERC 2021: amiodarone 300 mg is FIRST-LINE after 3 shocks in VF/pulseless VT. Lidocaine 100 mg is the ALTERNATIVE if amiodarone unavailable — not the preferred agent.
- CNS toxicity sequence: perioral tingling/metallic taste (early warning) → dizziness → confusion → seizures → coma. Reduce infusion rate at first sign.
- Hepatic flow dependency: in acute MI with reduced cardiac output, hepatic blood flow falls — lidocaine accumulates rapidly even at standard doses. Use lowest effective rate.
- Lipid emulsion antidote (Intralipid 20%): for severe local anaesthetic toxicity — 1.5 mL/kg IV bolus. AAGBI protocol.
- Standard prep: 500 mg in 500 mL 5% glucose = 1 mg/mL. Rate 1 mL/min = 1 mg/min.
Contraindications
- Sino-atrial disorder
- All degrees of AV block (without pacemaker)
- Wolff-Parkinson-White syndrome
- Severe heart failure (extreme caution)
Side effects
- CNS toxicity — progressive: dizziness, perioral numbness, confusion, seizures, coma
- Cardiac conduction depression (toxic doses)
- Hypotension
- Respiratory depression
Interactions
- Beta-blockers — additive cardiac conduction depression
- Cimetidine/propranolol — reduce lidocaine clearance; increase toxicity risk
Monitoring
- Continuous ECG
- Blood pressure
- CNS signs (confusion, drowsiness)
- Lidocaine plasma levels if prolonged infusion (therapeutic: 1.5-5 mcg/mL)
Reference: BNFc; BNF 90; ERC Resuscitation Guidelines 2021; AAGBI Local Anaesthetic Toxicity Guidelines; SPC Xylocard. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Revised Cardiac Risk Index (RCRI / Lee Index) · Perioperative Risk
- Vasoactive-Inotropic Score (VIS) · Inotropic Support
- Corrected QT Interval (Bazett) · ECG
- Cardiac Output (Fick Method) · Haemodynamics
- Revised Cardiac Risk Index (RCRI) · Pre-operative Risk
Drugs
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines